## Abstract Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is a promising cancer therapeutic agent because of its tumor selectivity. TRAIL is known to induce apoptosis in cancer cells but spare most normal cells. In this study, we examined whether treatment of docetaxel (DTX) can e
Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells
✍ Scribed by A. Munshi; T. McDonnell; R. Meyn
- Publisher
- Springer
- Year
- 2002
- Tongue
- English
- Weight
- 154 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) is a promising cancer therapeutic agent because of its tumor selectivity. TRAIL is known to induce apoptosis in cancer cells but spare most normal cells. In the previous study [Yoo and Lee, 2007], we have reported that hype
## Abstract Prostate cancer is associated with the inability of prostatic epithelial cells to undergo apoptosis rather than with increased cell proliferation. Prostate apoptosis response‐4 (Par‐4) is a unique pro‐apoptotic molecule that is capable of selectively inducing apoptosis in cancer cells w
## Abstract Many tumors constitutively express high levels of the inducible form of proinflammatory enzyme, cyclooxygenase‐2 (COX‐2). Increased COX‐2 expression is associated with tumor cell resistance to many cytotoxic chemotherapy drugs. Furthermore, increased resistance to cytotoxic antitumor dr